合生制剂改变脂肪肝患者肠道菌群,但未缓解病症
创作:王文东 审核:兵兵 2020年02月21日
  • 纳入104例非酒精性脂肪肝患者,分别接受合生制剂(果寡糖+BB-12)和安慰剂,干预10-14月;
  • 合生制剂组起始和干预结束时肝脏脂肪百分比值分别为32.3±24.8%和28.5±20.1%,安慰剂组为31.3±22%和25.2±17.2%;
  • 两组间肝脂肪减少无明显差异,只有体重降低与肝脂肪显著减少相关;
  • 相比起始,合生制剂组粪便中双歧杆菌和粪杆菌属比例更高,震颤杆菌和别样杆菌降低,安慰剂组未见改变;
  • 粪便菌群组成改变与肝脂肪或纤维化标志物无关。
主编推荐语
兵兵
人群干预研究。由果寡糖(4g*2次/天)+动物双歧杆菌乳亚种BB-12(1百亿)组成的合生制剂干预非酒精性脂肪性肝病(NAFLD)患者约一年时间,结果患者体内的肠道菌群发生改变,但是其肝脏脂肪含量并未降低,纤维化程度也并未缓解;而患者体重降低与肝脏脂肪化和纤维化改善存在相关性。本研究还观测到特定菌群的改变与炎症反应相关,因此文章建议合生制剂干预菌群可以用于NAFLD患者炎症和免疫相关参数的研究。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:17.373]

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

一项关于非酒精性脂肪肝患者的随机试验中,合生元改变粪便微生物群落,但未改变肝脂肪化或纤维化

10.1053/j.gastro.2020.01.031

2020-01-24, Article

Abstract & Authors:展开

Abstract:收起
Background & Aims: Dysbiosis of the intestinal microbiota has been associated with nonalcoholic fatty liver disease (NAFLD). We investigated whether administration of a synbiotic combination of probiotic and prebiotic agents affected liver fat content, biomarkers of liver fibrosis, and the composition of the fecal microbiome in patients with NAFLD.
Methods: We performed a double-blind phase 2 trial of 104 patients with NAFLD in the United Kingdom. Participants (mean age, 50.8±12.6 y; 65% men; 37% with diabetes) were randomly assigned to groups given the synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subsp. lactis BB-12; n=55) or placebo (n=49) for 10–14 months. Liver fat content was measured at the start and end of the study by magnetic resonance spectroscopy and liver fibrosis was determined from a validated biomarker scoring system and vibration-controlled transient elastography. Fecal samples were collected at the start and end of the study and fecal microbiomes were analyzed by 16S rDNA sequencing.
Results: Mean baseline and end of study magnetic resonance spectroscopy liver fat percentage values were 32.3%±24.8% and 28.5%±20.1% in the synbiotic group and 31.3%±22% and 25.2%±17.2% in the placebo group. In the unadjusted intention to treat analysis, we found no significant difference in liver fat reduction between groups (β=2.8; 95% CI, –2.2 to 7.8; P=.30). In a fully adjusted regression model (adjusted for baseline measurement of the outcome plus age, sex, weight difference, and baseline weight), only weight loss was associated with a significant decrease in liver fat (β=2; 95% CI, 1.5–2.6; P=.03). Fecal samples from patients who received the synbiotic had higher proportions of Bifidobacterium and Faecalibacterium, and reductions in Oscillibacter and Alistipes, compared with baseline; these changes were not observed in the placebo group. Changes in composition of fecal microbiota were not associated with liver fat or markers of fibrosis.
Conclusions: In a randomized trial of patients with NAFLD, 1 y administration of a synbiotic combination (probiotic and prebiotic) altered fecal microbiomes but did not reduce liver fat content or markers of liver fibrosis. clinicaltrials.gov no: NCT01680640.

First Authors:
Eleonora Scorletti

Correspondence Authors:
Eleonora Scorletti

All Authors:
Eleonora Scorletti,Paul R Afolabi,Elizabeth A Miles,Debbie E Smith,Amal Almehmadi,Albandri Alshathry,Caroline E Childs,Stefania Del Fabbro,Josh Beavis,Helen E Moyses,Geraldine F Clough,Jaswinder K Sethi,Janisha Patel,Mark Wright,David J Breen,Charles Peebles,Angela Darekar,Richard Aspinall,Andrew J Fowell,Joanna K Dowman,Valerio Nobili,Giovanni Targher,Nathalie M Delzenne,Laure B Bindels,Philip C Calder,Christopher D Byrne

评论